What Is Retatrutide? A Research Overview of the Triple Agonist GIP/GLP-1/Glucagon Peptide

Retatrutide is an experimental synthetic peptide developed by Eli Lilly and investigated as a triple agonist of the GIP, GLP-1, and glucagon receptors. Unlike single-target GLP-1 receptor agonists such as semaglutide, retatrutide is being studied for its capacity to activate three distinct metabolic hormone receptor pathways through a single molecule, a design that places it in a separate category from both mono- and dual-agonist compounds currently in clinical use.

Doctor Medica provides licensed medical professionals with research-based information across peptide categories, including retatrutide. Professionals looking to buy retatrutide for research purposes can contact the Doctor Medica team for guidance on sourcing and documentation.

This article explores retatrutide’s identity, naming history, structural composition, and receptor activity. It also explains how its triple-agonist mechanism differs from that of GLP-1 mono-agonists and GLP-1/GIP dual agonists.

Key Takeaways

• Retatrutide is an investigational triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously.
• It is identified in research literature under the Eli Lilly compound designation LY3437943.
• Its defining distinction is simultaneous activation across three receptor systems, placing it in a separate category from GLP-1 mono-agonists and GLP-1/GIP dual agonists.

About: Doctor Medica is your trusted all-in-one supplier, offering a range of high-quality medical injectables and supplies. We offer a worry-free experience in searching for the best and most popular products on the market, like retatrutide. Whether for health professionals, plastic surgeons, dermatologists, licensed estheticians, or other specialists, we can offer genuine, brand-name products you may need. With Doctor Medica, we prioritize serving you better to improve the patient’s quality of life.

What Is Retatrutide? Defining the Triple Agonist Mechanism

Retatrutide is a synthetic investigational peptide designed to activate three hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. It is therefore classified as a GIP/GLP-1/glucagon triple receptor agonist.[1][2]

“Triple agonist” refers to a single molecule that activates three separate receptor pathways. This distinguishes retatrutide from GLP-1 receptor agonists such as semaglutide, which primarily target the GLP-1 receptor, and dual agonists such as tirzepatide, which act on GLP-1 and GIP receptors without activating the glucagon receptor.[3]

This three-receptor profile is a major reason retatrutide has drawn interest in metabolic research. GLP-1 signaling is associated with appetite regulation and glucose control, while GIP contributes to incretin signaling and broader metabolic processes. Glucagon receptor activity is also being studied for its potential influence on energy expenditure and hepatic metabolism. Retatrutide brings these three mechanisms together within a single investigational peptide.[1][3]

What Is Retatrutide Called in Research Literature?

Retatrutide is now the name most widely used in clinical and scientific literature. Earlier structural pharmacology papers and trial records may instead refer to the compound by Eli Lilly’s research code, LY3437943, which served as its main identifier before the name retatrutide became established.[3]

Eli Lilly developed the compound within its broader incretin and metabolic disease research program. The company describes retatrutide as an investigational once-weekly triple-hormone receptor agonist that activates GIP, GLP-1, and glucagon receptors with a single molecule.[4] This development history is important because retatrutide was designed as a next-generation incretin therapy rather than as a simple modification of an existing GLP-1 agent.

Its two identifiers also reflect different stages and contexts of development. Retatrutide is the international nonproprietary name used in clinical research, while LY3437943 remains common in earlier pharmacology papers and trial documentation. Because the compound has not yet received regulatory approval, it does not have an approved brand name.

What Is Retatrutide Made From? Structural and Compositional Overview

Retatrutide is a peptide compound composed of amino acid units arranged in a defined sequence. Structurally, it belongs to the class of engineered incretin-related peptides designed to interact with class B G protein-coupled receptors, specifically GLP-1R, GIPR, and GCGR. [3]

Class B G protein-coupled receptors respond to peptide hormones involved in metabolic regulation. GLP-1R, GIPR, and GCGR all belong to this receptor family and share structural characteristics that enable the engineering of a single peptide capable of engaging all three.[3]

Structural studies describe retatrutide as an acylated peptide agonist designed to activate these receptor systems in a single molecule. The acylated modification helps extend the compound’s pharmacologic activity, an approach also used in other long-acting incretin-based peptides. This feature supports the once-weekly administration schedule evaluated in clinical trials.[3]

For research professionals, the key distinction is that retatrutide is not simply a GLP-1 analogue with additional components. It is a purpose-built synthetic peptide designed to coordinate activity among three related yet functionally distinct receptor pathways. Its triple-receptor profile therefore provides a more accurate description of the compound than any single hormone classification.

What GLP Is Retatrutide? Understanding Its Receptor Class

Retatrutide is frequently grouped with GLP-1 receptor agonists because GLP-1R activation is part of its mechanism of action. That classification is incomplete. The correct designation is a GIP/GLP-1/glucagon triple agonist, and the distinction matters for accurate interpretation of the compound’s research data. [1][2]

GLP-1 receptor agonism accounts for only one part of retatrutide’s three-receptor mechanism. Its GLP-1 activity is important, but it does not fully explain the compound’s pharmacologic profile.

This receptor classification reflects a meaningful difference in molecular design. Mono-agonists act through a single receptor pathway, while dual agonists coordinate activity across two pathways. Retatrutide is classified as a triple agonist because it is a single molecule designed to activate GLP-1R, GIPR, and GCGR.[3] The distinction is not simply a matter of greater potency; each class engages a different combination of biological pathways.

For this reason, retatrutide should not be interpreted through the same framework used for semaglutide or tirzepatide. The compounds differ in receptor coverage and in the metabolic mechanisms being investigated. When reviewing retatrutide trial data, professionals should therefore treat its triple-receptor architecture as the starting point for comparison.[3]

Who Is Retatrutide Being Researched For?

Retatrutide is under investigation in metabolic research populations, primarily adults with obesity, people with obesity-related complications, and adults with type 2 diabetes. Phase 2 research evaluated retatrutide across these groups, with separate trial arms assessing weight-related and glycemic outcomes. [1][2]

Phase 2 and Phase 3 Research Populations

The Phase 2 obesity trial included adults without type 2 diabetes who had a body mass index of at least 30, or at least 27 with one or more weight-related comorbidities. A separate Phase 2 trial enrolled adults with type 2 diabetes who were receiving a stable background treatment regimen. Both studies included several dose groups to examine dose-response patterns, a common feature of Phase 2 research.[1][2]

Lilly’s 2026 materials describe Phase 3 programs involving adults with obesity or overweight and related comorbidities, as well as separate cohorts of adults with type 2 diabetes.[4][5] These populations remain clinical research groups rather than approved treatment indications. At the time of writing, retatrutide has not received regulatory approval for clinical use.

Interest in retatrutide within medical weight-loss research has grown because clinical trials have reported substantial reductions in body weight among participants. These findings should still be interpreted as investigational evidence, not as a treatment recommendation or commercial product claim. For protocol-level detail, professionals may also find it useful to review retatrutide dosing to learn in depth about escalation schedules and research-context dosing parameters.

How Does Retatrutide Work Differently From Other GLP-1 Agents?

The key distinction is architectural. GLP-1 receptor agonists act through a single receptor system. Dual agonists extend this by adding GIP receptor activity alongside GLP-1 receptor activity. Retatrutide incorporates glucagon receptor agonism into the same molecular framework, engaging a third metabolic pathway that neither mono- nor dual-agonist compounds address. [3]

The rationale behind triple agonism is that coordinated activation of three receptor systems may affect multiple metabolic pathways simultaneously. GLP-1 and GIP contribute to incretin-mediated glucose regulation and appetite signaling. At the same time, glucagon receptor activity is being studied for its potential influence on energy balance, hepatic fat metabolism, and total energy expenditure.[1][3]

What Does the Glucagon Receptor Pathway Specifically Contribute?

The glucagon receptor component is the main feature that distinguishes retatrutide from earlier incretin-based compounds. Tirzepatide combines GLP-1 and GIP receptor activity and has demonstrated effects on glucose regulation and body weight in approved clinical use. Retatrutide extends that approach by adding glucagon receptor agonism, introducing another metabolic pathway into the same molecular framework.

Glucagon is best known for increasing blood glucose by stimulating hepatic glucose production, which may seem counterintuitive for a compound being studied for weight and glycemic outcomes. The working hypothesis is that, within retatrutide’s co-agonist design, activation of the glucagon receptor may increase energy expenditure and support hepatic fat oxidation. At the same time, concurrent GLP-1 and GIP activity may help offset the glucose-raising effects associated with glucagon alone.[1][3] Ongoing Phase 3 research will help clarify how this combined mechanism translates into clinical outcomes.

For research professionals, glucagon receptor engagement is arguably the most novel aspect of retatrutide’s design. It reflects a broader hypothesis that coordinated signaling across three metabolic receptors may produce effects that differ from those achieved through GLP-1 alone or through combined GLP-1 and GIP agonism. Whether those theoretical advantages are confirmed will depend on the results of larger clinical studies.

Compared with semaglutide, retatrutide is not simply a modified GLP-1 agent but a structurally distinct compound with broader receptor activity. Compared with tirzepatide, it targets a third receptor. This difference in receptor scope provides the basis for evaluating retatrutide alongside earlier incretin therapies. However, cross-trial comparisons should be interpreted cautiously because study populations, protocols, and compound mechanisms may differ.[3]

The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.

Citations

[1] Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–hormone-receptor agonist retatrutide for obesity. N Engl J Med. 2023;389:514-526. doi:10.1056/NEJMoa2301972

[2] Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomized, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023. https://pubmed.ncbi.nlm.nih.gov/37385280/

[3] Li W, Wang R, Zhang C, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discov. 2024. https://www.nature.com/articles/s41421-024-00700-0

[4] Eli Lilly and Company. Lilly’s Triple Agonist, Retatrutide, Demonstrated Significant Reductions in A1C and Weight in First Phase 3 Trial for Treatment of Type 2 Diabetes. Published March 19, 2026. Accessed July 2, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-demonstrated-significant

[5] Eli Lilly and Company. Lilly’s Triple Agonist, Retatrutide, Delivered Powerful Weight Loss in Pivotal Phase 3 Obesity Trial. Published May 21, 2026. Accessed July 2, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss